NEW YORK – Revvity said Thursday that it will provide DNA sequencing services to help identify rare genetic conditions in newborns for Genomics England's Generation Study.
The study involves the screening of up to 100,000 newborns for more than 200 rare genetic disorders, and the findings will be used to inform decisions on the use of whole-genome sequencing in newborn screening.
The new agreement expands on a previous partnership announced in November under which Revvity's Omics laboratory in Manchester, UK, would extract DNA from cord blood from samples collected from newborns for the study.
Revvity said it will now be able to provide an end-to-end sample prep and sequencing solution with a localized lab facility. According to its website, Revvity's newborn sequencing research workflow comprises sample collection and extraction, laboratory LIMS, sample quality control and quantification, automated library preparation and QC, sequencing using Element Biosciences and Illumina platforms, and bioinformatics analyses.
"Our complete solution and localized lab facility help us deliver timely and reliable sequencing data in support of this critical program that strengthens newborn health," Madhuri Hegde, Revvity's senior VP and CSO, said in a statement. "Revvity's expansive global laboratory network combined with our next-generation sequencing solutions and workflows for newborn screening uniquely positions us to lead this and similar initiatives, setting a standard for future programs."
Financial terms of the agreement were not disclosed.